New therapeutic option for irritable bowel syndrome: Serum-derived bovine immunoglobulin

Table 1 Presentation of irritable bowel syndrome patients with diarrhea

Patient No./age (yr)/gender	Primary symptoms	Comorbidity	Other GI therapy	SBI therapy/duration	Outcome
IBS-D 1/24/M	Diarrhea, frequency	Chronic urethritis	Low FODMAP diet,	Ongoing	Complete resolution of symptoms
	urgency,	ulcerative proctitis	mesalamine	32 wk
	ABD pain
IBS-D 2/36/F	Diarrhea	Hypothyroidism	None	Ongoing	Marked improvement in urgency and diarrhea
	urgency	anxiety,		18 wk
	incontinence	depression
IBS-D 3/63/M	Diarrhea	Eosinophilic esophagitis,	Pantoprazole	Ongoing	Complete resolution of symptoms
	Flatulence,	RIH,		27 wk
	ABD cramps,	BPH
	urgency
IBS-D 4/86/M	Loose stools,	COPD,	Domperidone	Ongoing	Marked improvement of urgency and diarrhea
	urgency,	lung cancer		12 wk
	cramping
IBS-D 5/36/F	Diarrhea,	Ulcerative colitis	Low FODMAP diet,	Ongoing	No ABD pain, Loose stools/diarrhea improved
	severe ABD pain		mesalamine	12 wk
IBS-D 6/87/F	Diarrhea,	Osteoporosis,	Perphenazine/amitriptyline,	Ongoing	Dramatic reduction in symptoms
	ABD pain,	GERD,	omeprazole	17 wk
	distention,	anxiety
	urgency
IBS-D 7/66/M	Diarrhea,	Hypertension,	Tramadol	Ongoing	Marked reduction in pain and urgency,
	urgency,	benign prostatic hyperplasia		16 wk	Formed bowel movements
	incontinenc,
	ABD pain

ABD: Abdominal; IBS-D: Irritable bowel syndrome with diarrhea; SBI: Serum-derived bovine immunoglobulin; GI: Gastrointestinal; GERD: Gastroesophageal reflux disease.